Liz O'Day

Founded in 2014, we’re America’s largest venture firm for individual investors and VC investing partner to over 11,000 individuals and institutions. Offerings include institutional-grade funds with large diversified portfolios and deal-by-deal investing through our Syndicates. Investment minimum is $10,000. • Top-20 VC Firm (Time Magazine ’25) • Top-Decile Investment Performance (Carta Benchmarks ‘25) • Top 20 VC Firm (CB Insights 24) • Top 50 Unicorn VC (Stanford GSB Research ‘25) • Top 3 Most Active US VC Firm (PitchBook ‘18 - ‘24) • Most Founder Friendly Investor List (Inc. Magazine ‘24) • Worlds Most Innovative Companies (Fast Company 22) • #1 Most Active Venture Firm in the US (PitchBook 22 & 23) • Top 20 Venture Firm (CB Insights 24) • Worlds Most Innovative Companies (Fast Company 22) • Portfolio of 1,600+ current and historical companies • 40+ full-time VC investors • Founders get access to our community of 850,000+ members and 6,000+ Experts. Offers of securities made only to eligible investors by formal offering documents describing risks, terms, and other important information that must be considered before investing. Example portfolio companies shown for illustrative purposes only, do not necessarily reflect investment outcomes that were or would be obtained by any AV fund or investor, and are not available to future investors, except potentially in follow-on investments. Venture capital investing involves substantial risk, including risk of loss of all capital invested. Past performance does not guarantee future results. The content on this account is intended solely for persons located in the U.S. and is not directed at, and must not be acted upon, by any person in the United Kingdom. UK residents seeking information about AV should refer only to communications issued by Alumni Ventures UK LLP, which provides information solely on a non-promotional basis and only distributes Financial Promotions to eligible recipients in accordance with UK law.

The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient. By combining the data from those tests with an individual’s medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans. Recognizing that a paradigm shift in medicine will not happen just because the science suggests it should, the Coalition spearheads a robust portfolio of activities in education and advocacy, including the Annual Personalized Medicine Conference at Harvard Medical School.

Mission: WEST is a learning community that provides women in the enterprise of science and technology with the inspiration, knowledge, and connections to reach their full potential. Our diverse membership represents industries ranging from information technology and biopharmaceuticals to cleantech and environmental sciences. WEST is a community and forum, for early, mid-career, executive, and entrepreneurial women in STEM careers. WEST members are committed to developing themselves as leaders through education, mentorship, networking, and information sharing. WEST encourages women to cultivate entrepreneurial thinking and creative risk-taking.

Olaris is a precision medicine company leveraging metabolomics and machine learning for the discovery and development of its myOLARIS™ diagnostics products, which aim to optimize treatments and outcomes for individual patients. Metabolite diagnostics empower therapeutic selection, treatment effectiveness monitoring, disease diagnosis, and target identification across indications and therapeutics areas, including oncology, solid-organ transplant, and neurodegeneration. Our mission is to remove the guesswork from medicine.